Project Grant HT9425261E428
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $4.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $4.199798 million on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct a Phase 1/2 study of HALK CAR T cells for patients with relapsed/refractory high-risk neuroblastoma. The award funds clinical trial design, patient enrollment, and immunotherapy development activities. Work will be performed in Boston, Massachusetts, with a period of performance through August 31, 2030....
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc., $4.199 million on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop optimized B7-H3 CAR T cells for children and young adults with sarcomas and other B7-H3–positive solid tumors. The award funds research and development of engineered T cell immunotherapy targeting pediatric and young adult solid tumors expressing the B7-H3 antigen. Work is performed in Boston,...
- The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
- The Department of the Army Medical Command awarded a $541,681 project grant to Dana-Farber Cancer Institute, Inc. to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. This award falls under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions for battlefield...
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $723,699 on July 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) for a project titled "Optimizing Immunotherapy for Pediatric Solid Tumors." The award covers research and development activities performed in Boston, Massachusetts, with a period of performance through July 14, 2029. The program supports basic, applied, and advanced biomedical research to transform health care for...
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $1.12 million under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2026, to support resource development to improve outcomes for blastic plasmacytoid dendritic cell neoplasm. The award funds basic and translational research over a four-year performance period ending August 31, 2030, with work performed in Boston, Massachusetts. The program supports innovative biomedical research to transform...
- The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc., $1,014,596 on July 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research optimizing immunotherapy for pediatric solid tumors. Performance runs through July 14, 2029, at the institute's Boston, Massachusetts location. The grant advances the Defense Health Agency's mission to transform health care for Service Members and the American public through innovative biomedical research,...
- The Dana-Farber Cancer Institute, Inc. was awarded a $267,000 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program to conduct pre-industrial studies of a first-generation dual-targeted, fine-tuned, immune-restoring chimeric antigen receptor T-cell therapy to achieve cures of clear cell renal cell carcinoma. The two-year award period runs from September 30, 2021 through September 30, 2023 and will support...
- The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
- <p>The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $559,999 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop novel digenic combination therapies for treatment of pancreatic cancer. The award runs through August 31, 2028, with work performed in Boston, Massachusetts. The assistance type is a project grant.</p>